Home22UA • FRA
add
BioNTech SE - ADR
Previous close
€120.20
Day range
€113.50 - €120.00
Year range
€69.70 - €124.60
Market cap
27.74B USD
Avg Volume
1.24K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (EUR) | Sep 2024info | Y/Y change |
|---|---|---|
Revenue | 1.24B | 39.04% |
Operating expense | 1.04B | 53.43% |
Net income | 198.10M | 23.35% |
Net profit margin | 15.91 | -11.32% |
Earnings per share | 0.81 | 20.90% |
EBITDA | 65.30M | -30.31% |
Effective tax rate | -24.83% | — |
Balance Sheet
Total assets
Total liabilities
| (EUR) | Sep 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 16.71B | 6.10% |
Total assets | 22.40B | 0.87% |
Total liabilities | 3.29B | 40.43% |
Total equity | 19.11B | — |
Shares outstanding | 239.74M | — |
Price to book | 1.51 | — |
Return on assets | 0.23% | — |
Return on capital | 0.27% | — |
Cash Flow
Net change in cash
| (EUR) | Sep 2024info | Y/Y change |
|---|---|---|
Net income | 198.10M | 23.35% |
Cash from operations | -638.90M | -178.76% |
Cash from investing | -142.10M | 88.47% |
Cash from financing | -7.90M | 97.46% |
Net change in cash | -752.10M | -12.12% |
Free cash flow | -684.45M | -217.91% |
About
BioNTech SE is a global biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
CEO
Founded
2008
Website
Employees
6,133
